Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TS-2
- Development stage
- Preclinical
- Lead developer
- 28-7 Therapeutics
- Modality
- Small Molecules
01
Overview
TS-2 is a small molecule inhibitor of the terminal uridyltransferases (TUTases) ZCCHC11 (also known as TUT4 or TENT3A) and ZCCHC6 (also known as TUT7 or TENT3B). Developed by Twentyeight-Seven Therapeutics, TS-2 is the weakly active enantiomer of the more potent lead compound TS-1. In preclinical research, TS-2 demonstrated significantly lower biochemical potency compared to TS-1, with IC50 values of 0.15 μM for ZCCHC11 and 1.8 μM for ZCCHC6. It is primarily utilized as a pharmacological control to validate the therapeutic potential of TUTase inhibition in suppressing glioblastoma cell proliferation and modulating RNA uridylation.
02
Targets
TENT4BTUT7 (Terminal uridylyltransferase 7)
Beyond the preview
Go deeper on TS-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TS-2.